To focus on the main business of innovative drugs, a well-known pharmaceutical company sells medical device business

Pharmaceutical Network Corporate News) Recently, Lizhu Pharmaceuticals announced that it has sold a 19.99 percent stake in Nico,000 of its medical device products business to independent third party Genesis Medtech, realizing the withdrawal of the project that has already been invested in the company, with a price of RMB 122 millionThe sale is expected to increase net profit to about RMB85.24 millionAmong them, it is worth noting that the announcement that the sale of equity effectively realized the company has invested in the project exit, so that the company more focused on innovative pharmaceutical industryin fact, in recent years, Lizhu Group is increasing technological innovation and research and development investment in innovative drugs, so this is not the first time Lizhu Pharmaceuticals to focus on the main industry to sell equityAs early as April 18, 2017, Lizhu Group announced that, in order to focus on the main biopharmaceutical industry, the company will hold a 100% equity transfer of Zhuhai Weixing Industrial, which directly led to a 3.284 billion net profit of shareholders of listed companiesit is understood that the main pharmaceutical products of the Lizhu Group research and development, production and sales, products covering preparation products,APIandintermediates, diagnostic reagents and equipmentOver the years through a variety of layout, has built a "Lizhu reagents and Lizhu single resistance to the Lizhu Sanmei and Lizhu gene" precision medical industry chainamong them: Lizhu reagents main IVD products, molecular diagnostics and chemical luminescenceThere are 12 projects under research, including 10 biologic preparation products, including CD20, HER2, TNFa, rhCG and PD-1, respectively, clinical I-III, rapid progress; With the company's important mono-anti-product injection recombinant humanized anti-PD-1 monoclonal antibody in July 2017 was approved by the U.SFDA to conduct Phase I clinical trials, the research and development capabilities of Lizhu mono-resistance have been in line with international standards, taking an important step on the road to internationalizationaccording to the 2019 annual report released by Lizhu Pharmaceuticals shows that last year, the company continued to independent innovation and high-barrier imitation as the concept of research and development, giving priority to the progress of the focus on research varieties, a number of products approved or reported for productionAt the same time, the company is continuously optimizing and adjusting the team of Lizhu monoantigen, focusing on the development of key projects in biopharmaceuticals, to promote clinical accelerationIt is reported that on June 4, 2019, Lizhu Pharmaceuticalannounc announced that the company's Sun Company Cardi Bio will invest 30 million yuan to subscribe for the new registered capital of Zunz Pharmaceuticals 3.111 million yuan, accounting for 10% of the registered capital of Zunz Pharmaceuticals after the completion of the capital increaseThis means that the company's additional layout of the field of biomedicine, is about to open a new chapter in the field of cell therapy research and development, but also in the field of innovative biopharmaceuticals, long-term research and development pipeline strategic layout of another important initiativein addition to, Lizhu Pharma has also initiated research and development in the cell therapy business area while further focusing on biopharmaceutical research and developmentAt the same time, its api research and development capacity is also continuously improved, fermentation research and development center successfully developed a number of high-end specialty raw materials drugsAs research and development projects increased and efficiency increased, the company's entry into clinical trials increased, and research and development costs increased by 33.5% year-on-year to 733 million yuanindustry insiders believe that in the future under the leadership of the new management team, Lizhu Group will further improve the research and development innovation system, increase the research and development of innovative drugs and high-end generic drug species, while in-depth mining with market potential and technical barriers in the product species, continue to promote the market-oriented evaluation of key drugs, the consistency of the relevant drugs evaluation work, and constantly optimize the layout of the product field to ensure the company's long-term sustainable developmentAnd with the company's innovative research and development results have landed, Lizhu Group may become a leading enterprise seinted by specialty drugs.